Systemic immunity in cancer

Hiam-Galvez, Kamir J; Allen, Breanna M.; Spitzer, Matthew H.

doi:10.1038/s41568-021-00347-z

Cited by 860 publications

(660 citation statements)

References 184 publications

(137 reference statements)

Supporting

Mentioning

642

Contrasting

Unclassified

Order By: Relevance

“…It has the potential to augment anti-tumor immunity ( Canti et al, 2010 ). It is known that generation of effective systemic anti-tumor immune responses has a great potential to eliminate tumors ( Bonavida and Chouaib, 2017 ; Gonzalez et al, 2018 ; Labani-Motlagh et al, 2020 ; Hiam-Galvez et al, 2021 ). PDT is capable of inducing immunogenic cell death, which is a cell death modality that stimulates immune responses against dead cell antigens ( Green et al, 2009 ; Kroemer et al, 2013 ; Ng et al, 2018 ).…”

Section: Photodynamic Therapy Combined With Other Therapy Modalitiesmentioning

confidence: 99%

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

2021

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has been used as an anti-tumor treatment method for a long time and photosensitizers (PS) can be used in various types of tumors. Originally, light is an effective tool that has been used in the treatment of diseases for ages. The effects of combination of specific dyes with light illumination was demonstrated at the beginning of 20th century and novel PDT approaches have been developed ever since. Main strategies of current studies are to reduce off-target effects and improve pharmacokinetic properties. Given the high interest and vast literature about the topic, approval of PDT as the first drug/device combination by the FDA should come as no surprise. PDT consists of two stages of treatment, combining light energy with a PS in order to destruct tumor cells after activation by light. In general, PDT has fewer side effects and toxicity than chemotherapy and/or radiotherapy. In addition to the purpose of treatment, several types of PSs can be used for diagnostic purposes for tumors. Such approaches are called photodynamic diagnosis (PDD). In this Review, we provide a general overview of the clinical applications of PDT in cancer, including the diagnostic and therapeutic approaches. Assessment of PDT therapeutic efficacy in the clinic will be discussed, since identifying predictors to determine the response to treatment is crucial. In addition, examples of PDT in various types of tumors will be discussed. Furthermore, combination of PDT with other therapy modalities such as chemotherapy, radiotherapy, surgery and immunotherapy will be emphasized, since such approaches seem to be promising in terms of enhancing effectiveness against tumor. The combination of PDT with other treatments may yield better results than by single treatments. Moreover, the utilization of lower doses in a combination therapy setting may cause less side effects and better results than single therapy. A better understanding of the effectiveness of PDT in a combination setting in the clinic as well as the optimization of such complex multimodal treatments may expand the clinical applications of PDT.

show abstract

Section: Photodynamic Therapy Combined With Other Therapy Modalitiesmentioning

confidence: 99%

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

2021

View full text Add to dashboard Cite

show abstract

“…Immune escape is facilitated by multiple mechanisms including loss of tumor antigens, decreased cancer cell immunogenicity, and formation of an immune suppressive microenvironment [70]. In addition, systemic factors can influence the fitness of the immune system and in doing so, contribute to immune evasion [71][72][73]. In this regard, the liver is well-recognized for its capacity to promote immune tolerance [74].…”

Section: A Role For Saa In Coordinating the Inflammatory Response To Cancermentioning

confidence: 99%

Serum Amyloid A Proteins and Their Impact on Metastasis and Immune Biology in Cancer

Lee

Beatty

2021

Cancers

View full text Add to dashboard Cite

Cancer triggers the systemic release of inflammatory molecules that support cancer cell metastasis and immune evasion. Notably, this biology shows striking similarity to an acute phase response that is coordinated by the liver. Consistent with this, a role for the liver in defining cancer biology is becoming increasingly appreciated. Understanding the mechanisms that link acute phase biology to metastasis and immune evasion in cancer may reveal vulnerable pathways and novel therapeutic targets. Herein, we discuss a link between acute phase biology and cancer with a focus on serum amyloid A proteins and their involvement in regulating the metastatic cascade and cancer immunobiology.

show abstract

“…Allison and Honjo in 2018 for the discovery of T-cell immune checkpoints, such as CTLA-4 and PD-1 [15,16]. Cancer immunotherapy, regarded as a third-generation cancer therapy, modifies the patient's own immune system to control or eliminate cancer [17]. To date, the typical types of cancer treatment are chemotherapy, radiation therapy, surgery, and a combination of those options.…”

Section: Emerging Application Of Immunotherapy For Cancermentioning

confidence: 99%

The Comprehensive “Omics” Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy

Yoon

Lee

Chae

et al. 2021

IJMS

View full text Add to dashboard Cite

In the past decade, immunotherapies have been emerging as an effective way to treat cancer. Among several categories of immunotherapies, immune checkpoint inhibitors (ICIs) are the most well-known and widely used options for cancer treatment. Although several studies continue, this treatment option has yet to be developed into a precise application in the clinical setting. Recently, omics as a high-throughput technique for understanding the genome, transcriptome, proteome, and metabolome has revolutionized medical research and led to integrative interpretation to advance our understanding of biological systems. Advanced omics techniques, such as multi-omics, single-cell omics, and typical omics approaches, have been adopted to investigate various cancer immunotherapies. In this review, we highlight metabolomic studies regarding the development of ICIs involved in the discovery of targets or mechanisms of action and assessment of clinical outcomes, including drug response and resistance and propose biomarkers. Furthermore, we also discuss the genomics, proteomics, and advanced omics studies providing insights and comprehensive or novel approaches for ICI development. The overview of ICI studies suggests potential strategies for the development of other cancer immunotherapies using omics techniques in future studies.

show abstract

Systemic immunity in cancer

Cited by 860 publications

References 184 publications

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

Serum Amyloid A Proteins and Their Impact on Metastasis and Immune Biology in Cancer

The Comprehensive “Omics” Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy

Contact Info

Product

Resources

About